Dual GLP-1/glucagon receptor agonists, including mazdutide, integrate appetite suppression with increased energy expenditure and fat oxidation, while triple GLP-1/GIP/glucagon agonists, such as retatrutide, further augment these mechanisms through multi-pathway receptor engagement
Maximum daily dose should not exceed 3,000 mg, with caution in patients with liver disease or alcohol use
The gradual titration schedule helps minimize early side effects, and most patients who complete the titration phase tolerate the medication well long-term
Common reasons include a limited response or side effects tolerance
Chm sc tuyt vi cho ln da mng manh trc khi bi, tia nng mt tri c hi, nhim, khin ln da trong mt mi, xn mu, gi nua v khng khe mnh
It may also influence hormones involved in weight regulation